Osteogenesis imperfecta is a rare genetic disorder characterised by fragile bones and reduced bone mass. Credit: Darwin Laganzon from Pixabay.

Rocket Pharmaceuticals has started treatment with its investigational gene therapy, RP-L201, in a Phase I/II clinical trial to treat severe Leukocyte Adhesion Deficiency-I (LAD-I).

RP-L201 is a lentiviral vector (LVV)-based therapy that contains autologous genetically modified CD34+ hematopoietic cells. Rocket licensed the product from the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) in Spain.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

LAD-I is a rare disorder caused by a mutation of the ITGB2 gene. The paediatric disease can lead to fatal infections as white blood cells lose the ability to leave the bloodstream to fight the infection.

Without a successful bone marrow transplant, severe LAD-I is associated with 60-75% mortality in the initial two years of life and survival beyond five years is rare.

The non-randomised, open-label Phase I/II study is designed to assess RP-L201 for the treatment of severe LAD-I in nine paediatric patients worldwide.

“Our hope is that patients would benefit from a one-time administration of autologous gene therapy.”

Phase I of the study will investigate the gene therapy’s safety and tolerability, while the Phase II portion will monitor the participants’ overall survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The survival will be established by the proportion of patients alive at the age of two and a minimum of one-year after infusion without allogeneic hematopoietic stem cell transplant (HSCT).

In addition, the Phase II portion will characterise the safety and toxicity of the RP-L201 infusion.

Rocket Pharmaceuticals CEO and president Gaurav Shah said: “LAD-I represents a major area of unmet medical need as most severely-afflicted patients die before the age of two in the absence of a hematopoietic stem cell transplant, which is associated with graft-versus-host disease.

“Our hope is that patients would benefit from a one-time administration of autologous gene therapy facilitated with busulfan conditioning. This process does not require immunosuppression and eliminates the risk of graft-versus-host disease.”

The company expects to complete the Phase I/II trial in 2023.